ClinicalTrials.gg
Status unknownNCT03658070Updated Aug 21, 2020

A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours

A Phase 1 interventional study of XY0206 in Advanced or Metastatic Solid Tumours, sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd. Status unknown at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-21.

Sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

  1. To observe the safety and tolerability of oral XY0206 in patients with advanced/metastatic malignant solid tumor in China, and observe the drug dose limiting toxicity (DLT) to establish the maximum tolerated dose (MTD) in humans.
  2. To investigate the pharmacokinetic (PK) characteristics, pharmacodynamics (PD) characteristics, and PK/PD correlation of single and multiple doses of XY0206 in patients with advanced/metastatic malignant solid tumors to provide dose selection basis for clinical studies;
  3. To evaluate the effect of standard meal on main PK parameters of XY0206;
  4. To determine the metabolites of XY0206 in patients with advanced/metastatic malignant solid tumor.
  5. To explore the correlation between PK and QTcF.
  6. Preliminary investigates the effectiveness of XY0206 in patients with advanced/metastatic malignant solid tumors.
02

Conditions studied

  • Advanced or Metastatic Solid Tumours
03

In context

Lead sponsor

Shijiazhuang Yiling Pharmaceutical Co. Ltd is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet all of the following criteria before entering the group:

    1. Patients with advanced/ solid tumor (such as non-small cell lung cancer, gastrointestinal stromal tumor, renal cell carcinoma, pancreatic cancer, etc.) who have failed standard treatment with histological or cytological diagnosis, have no effective treatment, or have after treatment.
    2. Patients with measurable or evaluable tumor lesions (1.1 version of efficacy evaluation criteria).
    3. The age is 18\~70 years old (including upper and lower limit), and there is no restriction on male and female (for participating in the extended trial)Of patients with a sex ratio of not less than 30%).
    4. Physical condition ≤2.
    5. Expected survival ≥3 months.
    6. at 19≤BMI≤30, BMI = weight (kg)/height 2 (m2).
    7. Liver function: \<2.5×, ALT\<2.5×ULN, total \<1.5×ULN.
    8. Blood biochemistry: Serum potassium and sodium levels are within the range of normal laboratory values (if researchers and physiciansThe overseer assesses results beyond the normal range to be of no clinical significance and the patient canInto the group; If the drug can be controlled within the normal range during the screening period, the patient canTo enroll).
    9. Renal function: serum creatinine (Scr) ≤1.5×ULN or calculated rate(Ccr) >60mL/min Ccr calculation formula: male Ccr=[(140- age)× weight(kg)] / [0.818 x Scr (mu mol/L)], women Ccr = 0.85 x [(140 - age) by weight(kg)] / [0.818 x Scr (mu mol/L)].
    10. blood routine: count of > 80×109/L, of > 90g/L, neutrophil pair count of > 1.5×109 /L.
    11. Urine routine: urinary protein - or 1+, or 24-hour urinary protein \<1 g [Note: if due to urinary tractTransient abnormalities of the above urinary protein due to infection and other causes returned to normal after retesting.You can also consider enrolling; Subjects without proteinuria symptoms may also be considered for inclusion.
    12. Coagulation function: International standardized ratio \< 1.5.
    13. No other antitumor concomitant therapy (including with antitumor effects).
    14. Women of childbearing age and men agreed to use it throughout the study period and within 6 months after completion of treatmentRegular that is effective enough.
    15. Understand and voluntarily sign written , and have the willingness and ability to complete regular visits and treatmentTreatment planning, laboratory examination and other test procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients cannot participate in this clinical study if they meet any of the following conditions:

    1. Pregnant or lactating women.
    2. Tested positive for (HIV).
    3. The active period of or infection is known to be associated with abnormal liver function, and antiviral drugs are required.
    4. Severe trauma, ulcer or fracture at screening time.
    5. A history of uncontrolled epilepsy, central nervous system disease or mental illness.
    6. Symptomatic or uncontrolled or meningeal diseases.
    7. diabetes or hypertension with poor drug control (under optimal drug treatment, fasting blood glucose >7mmol/L, or blood pressure > 150/100mmhg).
    8. Uncontrolled thyroid dysfunction.
    9. Persistent arrhythmias of version 4.03 or above, level ≥2, atrial fibrillation of any level.
    10. Cardiac (ECHOcardiography) below 50%.
    11. patients with prolonged history of (>450ms for male and >470ms for female).
    12. Have a history of severe drug allergy (NCI CTCAE level ≥3 according to version 4.03 or above) and may be allergic to test drug ingredients; Has been treated with or is allergic to sunitinib malate.
    13. for the first time to give medicine taken within 4 weeks before have significant effects on P450 metabolic pathway of drugs (for example: ketoconazole, itraconazole, clarithromycin, aza that wei, indiana that wei, naphthalene sanzuotong, that of the wei and the wey, ShaKui the wey, terry toxin, voriconazole, dexamethasone, phenytoin, carbamazepine, rifampicin, dean, rifampicin and dean at the cloth, phenobarbital, st. John's wort, etc.) or to eat within 48 h before delivery of P450 metabolic enzyme pathways have a significant impact on food (such as grapefruit and food containing grapefruit).
    14. Received any experimental drug therapy within 6 weeks prior to initial administration.
    15. for the first time six weeks before the treatment, patients treated with anti-tumor therapy (chemotherapy, radiation therapy, biological therapy, or hormone therapy) (note: for anti-tumor small molecules targeting drugs, if the patient before the first test drugs, always use small molecules targeting drug has cleared more than 5 half-life, the patient may also be considered into the group]. Surgery was performed within 14 weeks prior to the first administration.
    16. patients have any limit test compliance of medical or psychiatric conditions, such as the central nervous system (CNS) leukemia, active control of bacterial infection, 3, or 4 bleeding, unstable angina, myocardial infarction, stroke or , pulmonary embolism, or into the group of six months before the test of catheter-related deep vein thrombosis, insulin-dependent diabetes mellitus (namely, type 1 diabetes), or non insulin-dependent diabetes but there were signs of small vascular disease, Adrenocortical dysfunction is known, malabsorption syndrome is known, and active diseases are known.
    17. Other severe acute or chronic medical or psychiatric conditions, or laboratory test abnormalities that may exacerbate the risks associated with participating in or taking test drugs, or that may interfere with the interpretation of test results. These conditions or abnormalities may be determined by the investigator to make the patient unfit to participate in the trial.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    XY0206-12.5mg

    Drug:XY0206;Dosage form:Tablet;Dosage:12.5mg;Include single dose treatment and multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-25mg

    Drug:XY0206;Dosage form:Tablet;Dosage:25mg;Include single dose treatment and multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-37.5mg

    Drug:XY0206;Dosage form:Tablet;Dosage:37.5mg;Include single dose treatment and multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-50mg

    Drug:XY0206;Dosage form:Tablet;Dosage:50mg;Include single dose treatment and multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-75mg

    Drug:XY0206;Dosage form:Tablet;Dosage:75mg;Include single dose treatment and multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-100mg

    Drug:XY0206;Dosage form:Tablet;Dosage:100mg;Include single dose treatment and multiple dose phase

    Drug: XY0206

Interventions

  • DrugXY0206

    Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.

06

What researchers measure

Primary outcomes

  1. DLT

    The occurrence of DLT.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  2. AE

    The occurrence rate of AE.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  3. ADR

    The occurrence rate of adverse drug reactions(ADR).

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  4. SAE

    The occurrence rate of SAE.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  5. Blood routine

    One of the laboratory tests.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  6. Urine routine

    One of the laboratory tests.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  7. Stool routine

    One of the laboratory tests.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  8. Blood biochemistry

    One of the laboratory tests.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  9. Coagulation function

    One of the laboratory tests.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  10. 12 lead ecg

    One of the laboratory tests.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  11. Body temperature

    One of the vital signs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  12. Blood pressure

    One of the vital signs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  13. Heart rate

    One of the vital signs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  14. Breathing

    One of the vital signs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  15. General condition

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  16. Skin

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  17. Head

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  18. Eyes

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  19. Ears

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  20. Nose

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  21. Throat

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  22. Heart

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  23. Lung

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  24. Chest

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  25. Abdomen

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  26. Limbs

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  27. Nerves

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  28. Back/spine

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  29. Lymph nodes

    One of the physical examination.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

Secondary outcomes

  1. AUCinf

    area under the concentration-time curve from the time of dosing extrapolated to time infinity.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  2. AUC0-24h

    area under the concentration-time curve from the time of dosing extrapolated to the 24h after dosing.

    Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours

  3. AUC0-72h

    area under the concentration-time curve from the time of dosing extrapolated to the 72h after dosing.

    Time frame: single dose phase:up to 72 hours

  4. AUC0-120h

    area under the concentration-time curve from the time of dosing extrapolated to the 120h after dosing.

    Time frame: single dose phase:up to 120 hours

  5. Peak Plasma Concentration (Cmax)

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  6. CL/F

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  7. Tmax

    The amount of time that a drug is present at the maximum concentration in serum.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  8. Cmin,ss

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  9. Cmax,ss

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  10. Cav,ss

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  11. PTF

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  12. RAUC1

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  13. RAUC2

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  14. RCmax

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  15. Kel

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  16. t1/2

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  17. Vz/F

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  18. AUC_%Extrap

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours

  19. Ae0-24h

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours

  20. Fe0-24h

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours

  21. Ae0-72h

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 72 hours

  22. Fe0-72h

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 72 hours

  23. Ae0-72h stool

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 72 hours

  24. CLr

    The PK parameters of the plasma sample.

    Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours

  25. Exploring the relative baseline change percentage of biomarkers (soluble VEGFR2).

    The PD parameters of XY0206.

    Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours

  26. Complete response rate (CRR)

    Effective parameters of XY0206.

    Time frame: through study completion,such as 30 months.

  27. Partial response rate (PRR)

    Effective parameters of XY0206.

    Time frame: through study completion,such as 30 months.

  28. Objective response rate (ORR)

    Effective parameters of XY0206.

    Time frame: through study completion,such as 30 months.

  29. Progression-free survival (PFS)

    Effective parameters of XY0206.

    Time frame: through study completion,such as 30 months.

07

Study locations

1 of 4 sites recruiting
  • National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100021, China
    Recruiting
  • The First Affiliated Hospital of Hainan Medical College
    Haikou, Hainan 570102, China
    Not yet recruiting
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2018 (actual). Primary completion is estimated for Dec 2020, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2018
First posted
Sep 5, 2018
StartActual
Dec 19, 2018
Primary completionEst.
Dec 2020
CompletionEst.
Dec 2020
Last update
Aug 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03658070
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Dec 19, 2018
Primary completion
Dec 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Aug 21, 2020

Study contacts

wei wang, master
Contact
wangwei001@yiling.cn
086-0311-66703017
Binghe Xu, MD
principal investigator · National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FLT3 Inhibitor XY0206

Start the discussion